AIMIA ANNOUNCES TORONTO STOCK EXCHANGE DEFERRAL OF CONSIDERATION OF NEW SHAREHOLDER RIGHTS PLAN
TORONTO, Dec. 12, 2023 /CNW/ - Aimia Inc. (TSX: AIM) ("Aimia") announced today that it has been notified by the Toronto Stock Exchange (the "TSX") that the TSX will defer consideration of the acceptance of Aimia's recently announced new, tactical shareholder rights plan (the "NewRights Plan") until: (i) such time as it determines that the appropriate securities commission will not intervene in the event of any take-over bid for Aimia, including Mithaq Canada Inc.'s outstanding unsolicited take-over bid to acquire all issued and outstanding common shares of Aimia (the "Hostile Bid") and (ii) the ratification of the New Rights Plan by the shareholders of Aimia within six months from the date of its adoption.
The deferral of acceptance of the New Rights Plan by the TSX does not affect the adoption or operation of the New Rights Plan, which will remain operative and effective until the day after the expiry of the Hostile Bid, unless terminated earlier.
A copy of the New Rights Plan is available under Aimia's profile on SEDAR+ at www.sedarplus.ca.
About AimiaAimia Inc. (TSX: AIM) is a holding company that makes long-term investments in private and public businesses through controlling or minority stakes. Aimia targets companies with durable economic advantages evidenced by a track record of substantial free cash flow generation over complete business cycles, strong growth prospects, and guided by strong, experienced management teams. Headquartered in Toronto, Canada, Aimia is positioned to invest in any sector, wherever a suitable opportunity can be identified worldwide. In addition, we seek investments that may efficiently utilize Aimia's operating and capital loss carry-forwards to further enhance shareholder value.
For more information about Aimia, visit www.aimia.com.
Forward-Looking StatementsThis press release contains statements that constitute "forward-looking information" within the meaning of Canadian securities laws ("forward-looking statements"), which are based upon our current expectations, estimates, projections, assumptions and beliefs. All information that is not clearly historical in nature may constitute forward-looking statements. Forward-looking statements are typically identified by the use of terms such phrases such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will", "would" and "should", and similar terms and phrases, including references to assumptions. Forward-looking statements in this press release include, but are not limited to, statements with respect to the Hostile Bid, termination of the New Rights Plan and TSX approval of the New Rights Plan. Forward-looking statements, by their nature, are based on assumptions and are subject to known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the forward-looking statement will not occur. The forward-looking statements in this press release speak only as of the date hereof and reflect several material factors, expectations and assumptions. Undue reliance should not be placed on any predictions or forward-looking statements as these may be affected by, among other things, changing external events and general uncertainties of the business. A discussion of the material risks applicable to us can be found in our current Management's Discussion and Analysis and Annual Information Form, each of which have been or will be filed on SEDAR+ and can be accessed at www.sedarplus.ca. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and we disclaim any intention and assume no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Aimia Inc.
Ausgewählte Hebelprodukte auf Hemispherx Biopharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hemispherx Biopharma
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Hemispherx Biopharma Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Hemispherx Biopharma Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Hemispherx Biopharma nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.